PHILADELPHIA — The investigational agent ecopipam reduces tic severity in children and adolescents with Tourette syndrome (TS) without exacerbating common psychiatric comorbidities, results of a new analysis suggest. As previously reported, the first-in-class dopamine-1 (D1) receptor antagonist reduced the primary endpoint of tic severity scores by 30% compared with placebo among 149 patients in the ...
.png)
Copyright © 2023 cape-breton.com. Toady's News. All Rights Reserved
